MHRA extends indication for AstraZeneca and Daiichi Sankyo's Enhertu

19 August 2022

Japanese drugmaker Daiichi Sankyo (TYO: 4568) and UK pharma major AstraZeneca (LSE: AZN) have announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has extended the conditional marketing authorization for Enhertu (trastuzumab deruxtecan) as a monotherapy for the treatment of adult patients in Great Britain with unresectable or HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens.

The marketing authorization is based on positive results from the DESTINY-Breast03 Phase III trial, which showed trastuzumab deruxtecan reduced the relative risk of disease progression or death by 72% versus trastuzumab emtansine in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

The safety of trastuzumab deruxtecan was evaluated in 257 patients with unresectable or metastatic HER2 positive breast cancer who received at least one dose of Enhertu (5.4mg/kg).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK